Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2024 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
February 13, 2024 22:40 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
February 13, 2024 16:01 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
February 01, 2024 16:01 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
January 08, 2024 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors

NAARDEN, The Netherlands and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
January 04, 2024 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Announces 2024 Strategic Priorities

-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to...
November 13, 2023 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial...
October 23, 2023 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
September 21, 2023 07:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation

-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain -- --...
September 20, 2023 08:00 ET | Source: NewAmsterdam Pharma N.V

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical...